anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Carcinogenicity studies of nafarelin were conducted in rats (24 months) at doses up to 100 µg/kg/day and mice (18 months) at doses up to 500 µg/kg/day using intramuscular doses (up to 110 times and 560 times the maximum recommended human intranasal dose, respectively). These multiples of the human dose are based on the relative bioavailability of the drug by the two routes of administration. As seen with other GnRH agonists, nafarelin acetate given to laboratory rodents at high doses for prolonged periods induced proliferative responses (hyperplasia and/or neoplasia) of endocrine organs. At 24 months, there was an increase in the incidence of pituitary tumors (adenoma/carcinoma) in high-dose female rats and a dose-related increase in male rats. There was an increase in pancreatic islet cell adenomas in both sexes, and in benign testicular and ovarian tumors in the treated groups. There was a dose-related increase in benign adrenal medullary tumors in treated female rats. In mice, there was a dose-related increase in Harderian gland tumors in males and an increase in pituitary adenomas in high-dose females. No metastases of these tumors were observed. It is known that tumorigenicity in rodents is particularly sensitive to hormonal stimulation.

Mutagenicity studies were performed with nafarelin acetate using bacterial, yeast, and mammalian systems. These studies provided no evidence of mutagenic potential.

Reproduction studies in male and female rats have shown full reversibility of fertility suppression when drug treatment was discontinued after continuous administration for up to 6 months. The effect of treatment of prepubertal rats on the subsequent reproductive performance of mature animals has not been investigated.
FIELD: medicine. ^ SUBSTANCE: invention relates to biology and medicine, namely to experimental models of immunologic states, and can be used for estimation of anti-ergotypic response to vaccination with polyclonally activated cells. For this purpose vaccination with splenocytes, activated by means of anti-CD3 antibodies and interleukin-2, by subcutaneous injections 1 time per week during 4 weeks. After that response of delayed-type hypersensitivity (DTH) is induced by introduction of activated splenocytes under aponeurosis of animal paw pad. Anti-ergotypic response is estimated by degree of DTH development. ^ EFFECT: implementation of method provides possibility of experimental reliable estimation of anti-ergotypic response in vivo, induced by polyclonally activated cells, and estimate its connection with changes of autoimmune disease course, performing control over autoimmune responses. ^ 1 dwg, 2 tbl, 3 ex
PURPOSE: Delirium is a common neurocognitive disorder in patients with advanced cancer and is associated with poor clinical outcomes. As a potentially reversible phenomenon, early recognition of delirium by identifying the risk factors demands attention. We aimed to develop a model to predict the occurrence of delirium in hospitalized patients with advanced cancer.
MATERIALS AND METHODS: This retrospective study included patients with advanced cancer admitted to the oncology ward of four tertiary cancer centers in Korea for supportive cares and excluded those discharged due to death. The primary endpoint was occurrence of delirium. Sociodemographic characteristics, clinical characteristics, laboratory findings, and concomitant medication were investigated for associating variables. The predictive model developed using multivariate logistic regression was internally validated by bootstrapping.
RESULTS: From January 2019 to December 2020, 2,152 patients were enrolled. The median age of patients was 64 years, and 58.4% were male. A total of 127 patients (5.9%) developed delirium during hospitalization. In multivariate logistic regression, age, body mass index, hearing impairment, previous delirium history, length of hospitalization, chemotherapy during hospitalization, blood urea nitrogen and calcium levels, and concomitant antidepressant use were significantly associated with the occurrence of delirium. The predictive model combining all four categorized variables showed the best performance among the developed models (area under the curve 0.831, sensitivity 80.3%, and specificity 72.0%). The calibration plot showed optimal agreement between predicted and actual probabilities through internal validation of the final model.
CONCLUSION: We proposed a successful predictive model for the risk of delirium in hospitalized patients with advanced cancer.
FIELD: nuclear medicine; applicable in production of radiopharmaceuticals based on strontium-89 radionuclide. SUBSTANCE: method includes preparation in nonradioactive zone of solution of the first type in form of aqueous solution of strontium chloride and solution of the second type in form of aqueous solution of sodium hydroxide. Solutions of the first and second types are mixed to obtain solution of the fourth type presenting aqueous solution of strontium chloride and sodium hydroxide. Solution of the fourth type is subjected to analytical control, and it is transferred from nonradioactive zone to radioactive zone. Added to fourth-type solution is solution of the third type in form of aqueous hydrochloride solution of strontium-89 radionuclide to produce end solution of the fifth type presenting aqueous solution of strontium chloride containing strontium-89 radionuclide and sodium chloride. End product is subjected to technological and analytical control. EFFECT: extended field of application of strontium chloride solution with strontium-89 radionuclide. 4 cl, 1 dwg
AECOPD patients who were ventilated with NAVA, PEEP was titrated and set at 0, 40%, 80% and 120% PEEPi. NAVA level was set to get the tidal volume of 6ml/kg.
BACKGROUND: The Nuss procedure is the primary treatment for pectus excavatum (PE), but patient expectations are not always met. In our unit, our standard approach in the last few years has been the routine application of two bars instead of one. We aimed to retrospectively assess the impact of this approach on patient satisfaction, quality of life (QoL) and safety.
METHODS: A retrospective study included 182 patients over 16 years old who underwent the Nuss procedure for PE between January 2007 and September 2021. Patients were categorized into one-bar or two-bar correction groups. Propensity score matching (PSM) was used, resulting in 30 patients in each group. Primary endpoints were QoL and cosmetic satisfaction, while secondary endpoints included complications and recurrence.
RESULTS: After PSM, both groups showed similar general characteristics. Patients treated with two bars reported fewer psychological complaints post-surgery (93.3% vs. 73.3%, p = 0.031). There were no significant differences in QoL improvement (96.7% in both groups, p = 0.197), perioperative complications (p = 0.771) or recurrence (one patient in the one-bar group, p = 1.000).
CONCLUSIONS: Our study reveals that patients undergoing the Nuss Procedure for PE with two bars exhibit comparable clinical outcomes and QoL to those with one bar. However, patients with two bars may have higher levels of psychological well-being and satisfaction, indicating potential benefits associated with this approach. These findings suggest potential advantages of the two-bar approach, but further research with larger sample sizes is warranted to confirm these observations.
Risk Summary

Published data from case reports with pancrelipase use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. Pancrelipase is minimally absorbed systematically; therefore, maternal use is not expected to result in fetal exposure to the drug. Animal reproduction studies have not been conducted with pancrelipase.

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Branched-chain amino acids (BCAAs) are essential for muscle protein synthesis and are widely acknowledged for mitigating sarcopenia. Oligonol® (Olg), a low-molecular-weight polyphenol from Litchi chinensis, has also been found to attenuate sarcopenia by improving mitochondrial quality and positive protein turnover. This study aims to investigate the effect of Olg on BCAA-stimulated protein synthesis in sarcopenia. In sarcopenic C57BL/6 mice and senescence-accelerated mouse-prone 8 (SAMP8) mice, BCAAs were significantly decreased in skeletal muscle but increased in blood serum. Furthermore, the expressions of membrane L-type amino acid transporter 1 (LAT1) and branched-chain amino acid transaminase 2 (BCAT2) in skeletal muscle were lower in aged mice than in young mice. The administration of Olg for 8 weeks significantly increased the expressions of membrane LAT1 and BCAT2 in the skeletal muscle when compared with non-treated SAMP8 mice. We further found that BCAA deprivation via LAT1-siRNA in C2C12 myotubes inhibited the signaling of protein synthesis and facilitated ubiquitination degradation of BCAT2. In C2C12 cells mimicking sarcopenia, Olg combined with BCAA supplementation enhanced mTOR/p70S6K activity more than BCAA alone. However, blocked LAT1 by JPH203 reversed the synergistic effect of the combination of Olg and BCAAs. Taken together, changes in LAT1 and BCAT2 during aging profoundly alter BCAA availability and nutrient signaling in aged mice. Olg increases BCAA-stimulated protein synthesis via modulating BCAA transportation and BCAA catabolism. Combining Olg and BCAAs may be a useful nutritional strategy for alleviating sarcopenia.
Amnesteem must not be used by patients who are or may become pregnant. There is an extremely high risk that life threatening birth defects will result if pregnancy occurs while taking Amnesteem in any amount, even for short periods of time. Potentially any fetus exposed during pregnancy can be affected. There are no accurate means of determining whether an exposed fetus has been affected.

Birth defects which have been documented following Amnesteem exposure include abnormalities of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands. Cases of IQ scores less than 85 with or without other abnormalities have been reported. There is an increased risk of spontaneous abortion, and premature births have been reported.

Documented external abnormalities include: skull abnormality; ear abnormalities (including anotia, micropinna, small or absent external auditory canals); eye abnormalities (including microphthalmia); facial dysmorphia; cleft palate. Documented internal abnormalities include: CNS abnormalities (including cerebral abnormalities, cerebellar malformation, hydrocephalus, microcephaly, cranial nerve deficit); cardiovascular abnormalities; thymus gland abnormality; parathyroid hormone deficiency. In some cases death has occurred with certain of the abnormalities previously noted.

If pregnancy does occur during treatment of a patient who is taking Amnesteem, Amnesteem must be discontinued immediately and the patient should be referred to an Obstetrician-Gynecologist experienced in reproductive toxicity for further evaluation and counseling.

     Special Prescribing Requirements

Because of Amnesteem’s teratogenicity and to minimize fetal exposure, Amnesteem is approved for marketing only under a special restricted distribution program approved by the Food and Drug Administration. This REMS is called iPLEDGE®. Amnesteem must only be prescribed by prescribers who are enrolled and activated with the iPLEDGE REMS. Amnesteem must only be dispensed by a pharmacy enrolled and activated with iPLEDGE, and must only be dispensed to patients who are enrolled and meet all the requirements of iPLEDGE (see PRECAUTIONS).
PURPOSE:To provide an anti-inflammatory agent having anti-inflammatory, antipyretic and analgesic activity, and extremely high safety, and suitable especially as an agent for external application, by using a specific unsaturated fatty acid, unsaturated alcohol or its esterified product as an active component. CONSTITUTION:The objective anti-inflammatory agent is produced by using a 8-24C unsaturated fatty acid having 1-3 C=C double bonds (preferably linoleic acid or linolenic acid), an unsaturated alcohol (preferably linoleyl alco hol, linolenyl alcohol, etc.) or its ester (preferably methyl ester, ethyl ester, etc.) as an active component. An antioxidant (e.g. dl-alpha-tocopherol) may be added to the above agent to improve the anti-inflammatory effect of the above compound. An anti-inflammatory, antipyretic and analgesic effect can be attained by applying the agent as an oral drug, injection, ointment, suppository, etc. It has high safety and low irritation.
Human adrenocorticotropic hormone(hACTH) was produced by multiplying human lymphoblastoid cells capable of producing hACTH in a warm- blooded host animal by transplantation, or growing the cells in a vessel supplied with the body fluid of a host animal. The cells were then recovered and induced to release hACTH. The lymphoblast cells were hybridoma cells obtd. by fusion of lymphoblast lines(Namalwa, BALL-1, TALL-1, NALL-1, and JBL) with chromophobic adenoma, pulmonary carcinoma. hACTH-inducers include vasopressin, atropine Me nitrate, insulin, glucagon, endotoxins, serotenin, or propanolol. hACTH stimulates the prodn. of the steroid hormone and has an ability to stimulate the secretion of insulin.
Crossover design. Order of agents is randomized. For this arm, the order will be IM olanzapine (1st clamp study) and IM aripiprazole (2nd clamp study).
FIELD: medicine. SUBSTANCE: the use of 9-diethylaminoethyl-2-phenylimidazo-[1,2-a]-benzimidazole nitrate exhibits an expressed inhibiting effect on hydrochloric acid and pepsin secretion that is accompanied with significant antiulcer action. At 7 hr pylorus ligation activity of proposed agent is 46 and 28.4-fold as compared with that for cimetidine and omeprazole, respectively, and by therapeutic index - by 10.5 and 55-fold, respectively. Agent decreases ulcer formation in stomach mucosa, and antiulcer effect of agent is enhanced. EFFECT: enhanced effectiveness of agent proposed. 2 dwg, 10 tbl
Participants randomized to the experimental group will receive full access to the Safe Step application and create their own individual program of strength and balance exercises. During 1 year the participants are recommended to exercise at least 30 minutes, 3 times a week and continuously progress their program. In addition they will every month receive an email with general falls prevention information in a short video.
The investigators will perform a randomized controlled trial of the impact of Child Adult Relationship Enhancement (CARE) plus peer mentor on increasing program adoption, acceptability, and appropriateness among 2-6 year old children and their parents at UNC Children's Primary Care Clinic. The investigators will also examine the effectiveness of CARE plus peer mentor on dysfunctional parenting and child behavior problems. Participants will be randomized to CARE plus peer mentor or standard CARE. Program attendance, acceptability, and appropriateness will be measured upon completion of the 6-week program. Dysfunctional parenting and child behavior will be measured at baseline and 6 weeks. The investigators will conduct semi-structured interviews among a sample of parents (\~20-30) in order to understand the impact of the peer mentors on program implementation, as well as barriers and facilitators to program initiation and long-term participation.
INTRODUCTION: Ellagic acid (EA) is a polyphenol that has shown health benefits in multiple experimental studies; mainly as an antioxidant, but also in hepatic steatosis, endothelial damage, hypertension, diabetes mellitus, visceral fat accumulation, dyslipidemia, insulin resistance, atherosclerosis, etc. There aren't studies that demonstrate the effectiveness of EA on MetS; since patients consume it without any prescription, it is important to evaluate the effect of the administration of EA on the components of metabolic syndrome, insulin sensitivity, and insulin secretion. The current design is a randomized double-blind, placebo-controlled, clinical trial. METHODS: Male and female volunteers between 30 to 59 years of age, with a diagnosis of MetS according to the International Diabetes Federation criteria will be included, whether they accept participating and signing the informed consent. Patients with one or more of the following criteria will be excluded: History of liver, kidney, heart, or thyroid disease; diabetes mellitus or arterial hypertension, alcohol, drug abuse or tobacco use, systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, fasting blood glucose ≥126 mg / dL, triglycerides ≥500 mg/dL, LDL cholesterol \>190 mg/dL; suspected or confirmed pregnancy, lactation, menopausal period \<1 year, hormonal contraceptive or replacement therapy, pharmacological, dietary or herbal therapy in the last 3 months before trial, allergy to any of the interventions. Patients included, may be withdrawn from the study if they meet any of the following conditions: Withdrawal of the informed consent, severe adverse reaction, loss of follow-up, treatment adherence \<80%; intolerance to EA or placebo. OBJECTIVES: The main objective is to evaluate the effect of EA or placebo on metabolic syndrome components, insulin sensitivity, and insulin secretion. HEADQUARTERS: The study will be carried out in the facilities of the Institute of Experimental and Clinical Therapeutics (INTEC), of the University Center of Health Sciences, at the University of Guadalajara. Guadalajara, Jalisco, Mexico.
BACKGROUND: Fractures present serious health challenges for older adults, including premature mortality and reduced quality of life. Obesity has become significantly prevalent in China. However, the association between obesity and fractures remains unclear. This study aimed to assess the association between obesity and fractures among Chinese women above 50 years of age.
METHODS: A prospective cohort study was designed based on the China Health and Nutrition Survey, using data from 1997 to 2015. The average follow-up duration was seven years. Trained investigators measured body mass index (BMI) and waist circumference (WC) at baseline. Obesity was defined according to World Health Organization recommendations. Waist-to-height ratio (W-HtR) was calculated, with 0.5 as the cutoff value. Onset of fractures, self-reported by the participants during the follow-up period, was the primary outcome. Cox hazard regression models were used to assess the association between BMI, WC, W-HtR and subsequent risk of fracture. A sensitivity analysis was conducted by multiple imputation of missing data on the variables at baseline.
RESULTS: A total of 2,641 women aged ≥ 50 years were involved in the study. In all the models, no significant association existed between BMI and fracture risk. However, women with WC ≥ 88 cm had significantly higher risk of fracture than those with WC < 80 cm according to both the unadjusted (HR = 1.744, 95% CI: 1.173-2.591) and adjusted models (HR = 1.796, 95% CI: 1.196-2.695). In addition, W-HtR and fracture risk were positively associated according to both the unadjusted (HR = 1.798, 95% CI: 1.230-2.627) and adjusted models (HR = 1.772, 95% CI: 1.209-2.599). Results of the sensitivity analysis were consistent with those of the above analyses.
CONCLUSIONS: Abdominal obesity increased the risk of all-cause fractures in Chinese women ≥ 50 years old. Intervention strategies and measures to prevent or address abdominal obesity would be helpful to decrease the fracture incidence.
The present invention relates to a zinc oxide-binding peptide sequence, a complex comprising the same, and a pharmaceutical composition comprising the complex. More specifically, the present invention relates to a zinc oxide-binding peptide sequence comprising an amino acid sequence of formula 1, a complex comprising the same, and a pharmaceutical composition comprising the complex. In the formula 1 of X_1, X_2, X_3, X_4, and L_5: X_1 is F, W, G, or A; X_2 is P, Q, V, F, or Y; X_3 is Y, F, I, or L; X_4 is P or D; and L_5 is a linker amino acid sequence. According to the present invention, a peptide sequence showing high affinity to a material formed by zinc oxide can be provided, and a peptide according to the present invention shows a relatively higher value in a binding force compared with previously reported peptides. Accordingly, the peptide of the present invention can be used to conveniently bond various biological molecules including proteins to materials formed by zinc oxide, and thus functionalities of the materials formed by zinc oxide may be enhanced and thus utilized in various fields. In particular, the present invention may be widely applied in medicine and pharmaceutical fields relating to materials, nano-technology, imaging, diagnosis, and development of new drugs.
PURPOSE:To provide a substance effective in improving cholesterol metabolism and capable of increasing serum HDL-cholesterol level of human and animal without causing side effect, by heat-treating wheat bran at a specific temperature and using the product as an active component. CONSTITUTION:Wheat bran heated at >=80 deg.C, preferably 95-200 deg.C is used as a substance for improving cholesterol metabolism. The heating is preferably carried out by using an extruder. It is preferably administered orally in the form of solid, however, it can be used as an additive of food (e.g. bread, cake, macaroni, noodle, etc.). It can be administered continuously over a long period at a high dose, preferably 10-30g without causing any problems nor lowering the original physiological activity such as prevention of constipation.
The nasopharyngeal suction with positive pressure method was employed in the sample group. In this method, the infant's head is turned to the side, 1-2 ml of PS is injected into the nostril with a syringe, and then positive pressure is exerted with the help of the end of the oxygen hose from the same nostril, with oxygen or air supply at 5-8 lt/min (if the baby requires oxygen, using an oxygen source) and the nasopharyngeal secretions are removed from the nostril into which PS has been not injected. The oxygen hose is held one centimetre away from the infant's nostril. The researchers prepared a guideline for nasopharyngeal suction with positive pressure based on the literature.
As minimally invasive procedure with numerous advantages compared with open surgery, laparoscopic surgery has been substantially performed worldwide. The creation of pneumoperitoneum during laparoscopic surgery, however, can have significant effects on the respiratory system including decreased respiratory system compliance, decreased vital capacity and functional residual capacity and atelectasis formation. These pathophysiologic changes may put patients at risk of postoperative pulmonary complications. Therefore, intraoperative mechanical ventilation, especially setting of positive end-expiratory pressure (PEEP) has an important role in respiratory management during laparoscopic surgery. Nevertheless, there is no consensus on the optimal PEEP level and the best method to set PEEP during laparoscopic surgery. In patients with acute respiratory distress syndrome, PEEP set according to pleural pressure measured by using esophageal balloon catheter significantly has beneficial effects in terms of oxygenation, compliance and possible mortality. The aim of this study is to determine whether setting of PEEP guided by measurement of pleural pressure would improve oxygenation and respiratory system compliance during laparoscopic surgery.